Navigation Links
FDA Approves the First Specific Treatment for Scorpion Stings
Date:8/3/2011

SILVER SPRING, Md., Aug. 3, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Anascorp, the first specific treatment for a scorpion sting by Centruroides scorpions in the United States.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Venomous scorpions in the U.S. are mostly found in Arizona. Severe stings occur most frequently in infants and children, and can cause shortness of breath, fluid in the lungs, breathing problems, excess saliva, blurred vision, slurred speech, trouble swallowing, abnormal eye movements, muscle twitching, trouble walking, and other uncoordinated muscle movements. Untreated cases can be fatal.

"This product provides a new treatment for children and adults and is designed specifically for scorpion stings," said Karen Midthun, M.D., director of the FDA's Center for Biologics Evaluation and Research. "Scorpion stings can be life-threatening, especially in infants and children."

Anascorp, Centruroides (Scorpion) Immune F(ab)2 (Equine) Injection, is made from the plasma of  horses immunized with scorpion venom. Anascorp may cause early or delayed allergic reactions in people sensitive to horse proteins. The manufacturing process for Anascorp includes steps to decrease the chance of allergic reactions and to reduce the risk of transmission of viruses that may be present in the plasma.

The effectiveness of Anascorp was based on results from a randomized, double-blind, placebo-controlled trial of 15 children with neurological signs of scorpion stings. These signs resolved within four hours of treatment in the eight subjects who received Anascorp, but in only one of the seven participants who received the placebo. The most common side effects were vomiting, fever, rash, nausea, itchiness, headache, runny nose, and muscle pain. In total, safety and efficacy data was collected from 1,534 patients in both open-label and blinded studies.

Anascorp was designated as an Orphan drug by FDA and received priority review. It is licensed to Rare Disease Therapeutics Inc., Franklin, TN, distributed by Accredo Health Group Inc., Memphis, TN, and manufactured by Instituto Bioclon, S.A. de C.V., of Tlalpan, Mexico, D.F.

For more information:

Product Approval

Consumer Update

Orphan Drugs

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Jan. 16, 2017 Summary ... to 2022", provides key market data on the North ... millions of US dollars, volume (in units) and average ... Absorptiometry (DEXA) and Quantitative Ultrasound (QUS). The report ... each of these market segements, and global corporate-level profiles ...
(Date:1/16/2017)...  Verathon ® Inc., a leading manufacturer and marketer of ... ® Spectrum TM Single-Use video laryngoscopes. The ... Ambient Light Reduction TM technology, which actively optimizes image quality. ... ... Introducing another bright idea from GlideScope(R) ...
(Date:1/16/2017)... -- When synthetic Fentanyl arrived on the streets in 2015, ... offered free samples, inviting would-be customers to test a newly-created ... The rapidly-growing demand for ... than morphine, has racked up a staggering death toll across ... dealer,s recorded fentanyl sales reveals that they have sold nearly ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... 2017 , ... To provide comfort and fuel during the ... category, announces a hearty and wholesome Winter Menu. Starting today, guests can enjoy ... Cranberry Crunch & Honey Parfait, Slow Cooked Smoky Chicken & Sausage Soup, and ...
(Date:1/16/2017)... New York, NY (PRWEB) , ... January 16, 2017 , ... ... the grand opening of a new showroom in East Hanover, New Jersey. , “We ... at Gym Source. “The new innovative in-store concept is designed to give clients a ...
(Date:1/16/2017)... ... ... Anybody who may be looking for a substance abuse rehabilitation program with a ... holistic treatment center for addiction located in Marne, MI. This video, which can be ... staff that visited the 2016 Recovery Palooza support event in nearby Grand Rapids. , ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Prairie’s award-winning Reflection® brand of custom seating systems has a well-earned reputation for ... with a platform for innovation and growth in the custom seating business, which ...
(Date:1/16/2017)... ... , ... St. Louisans are well-aware of the following facts at present:, ... to be having no effect on keeping this particularly bad strain of the flu away ... coughing, sneezing, or sniffling , These facts are well-known among the team ...
Breaking Medicine News(10 mins):